Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Completed · Phase 2 · Has a placebo group

Conditions studied: Alopecia Areata

In brief

This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.

Key facts

Study ID
NCT03941548
Run by
Concert Pharmaceuticals
People needed
66
Starts
2019-05-24
Expected to finish
2020-04-10
Last updated by the study team
2023-04-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.